Neal's got a box sitting on his bathroom counter. His doctor wrote the script 3 days ago. It's still unopened.His buddy at the gym won't stop talking about the one he's on. His wife lost thirty pounds on hers in four months. Neal's labs aren't where he wants them either. Part of him wants this box to be the answer. Part of him doesn't trust it yet.(Have you got a script sitting unopened because you don't trust it yet? See what the real research says at www.thecalltorise.com)If that's you too, this episode is for you.Ozempic, Wegovy, Mounjaro, Zepbound. One in eight adults in this country is currently on one of these drugs. Coach Brian breaks down the real research behind them, the actual trial data, not hype and not fear.-The GOOD: the weight loss numbers, the heart protection benefit most people never hear about, and the kidney trial that could change how you think about your own labs.-The BAD: the muscle loss nobody warns you about, the real cost most guys underestimate, and what happens to your body a year after you stop.-The UGLY: the counterfeit drug problem the FDA is actively trying to shut down, the vision risk worth knowing about, and the scare that turned out to be nothing after two years of research.Every claim in this episode is backed by a real study. Full sources and links are in the show notes so you can check the work yourself.This is the full picture. Use it to make the call with your own doctor instead of guessing.The Call To Rise is a 100-day fat loss challenge for driven men ready to take their body back. It combines strength training, personalized nutrition and real accountability. Most men drop 20 to 30 pounds and rebuild the confidence that comes with it.This program also works if you are dealing with high blood pressure, high cholesterol or Type 2 diabetes. It was built for those men too. Many men see those numbers move in the right direction alongside their weight loss.Inside the program you also join a Brotherhood of men doing the same work. Together you build a body you're proud of and start leading like the man you already are at work.This is your wake-up call to rise. Learn more and apply at www.thecalltorise.comCoach Brian Parana is not a doctor. Nothing in this episode is medical advice. Talk to your own physician before starting or stopping any medication.Fact-check sources:John Eng, Gila monster, exendin-4: VA Research 1992, Byetta approved 2005. | STEP 1 semaglutide: NEJM, 14.9% loss vs 2.4% at 68 weeks. | STEP 1 extension: Wilding 2022, regained two-thirds of lost weight within 1 year of stopping. | SURMOUNT-1 tirzepatide: NEJM, up to 22.5% avg loss, 52 lb at 15 mg.SURMOUNT-5: NEJM 2026, tirzepatide 20.2% loss vs semaglutide 13.7% at 72 weeks. | SELECT: Nature Medicine and Lancet, 20% reduction in MACE in adults with CVD and no diabetes. | FLOW: NEJM 2024, 24% reduction in kidney outcomes, 18

GLP-1s, The Good, the Bad, and the Ugly - 121

Get Started

Download the App